Ally Bridge Group Leads $150M Investment In Sorrento Therapeutics

Login to View

Ally Bridge Group, a Hong Kong-based healthcare private equity firm, has agreed to lead a US$150 million investment in NASDAQ-listed Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other diseases.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now


Already have an account or paid subscription? Log in


RELATED NEWS